"FDA's Draft Guidance on ‘Biosimilar’ Pathway Leaves Key Questions on Specific Clinical Data Requirements and Interchangeability Unanswered," Co-author, GenericsWeb newsletter InnSight, February 2012.

‹ Publications

Attorneys